The Medicare GLP-1 bridge, and what the $50 copay covers

Short answer

The Centers for Medicare and Medicaid Services runs a temporary GLP-1 bridge program that begins on July 1, 2026 and ends on December 31, 2027. Under it, eligible Medicare Part D enrollees pay a copay of $50 per month for covered brand-name GLP-1 products, against a net price of $245. The bridge covers brand-name products only, and eligibility is based on body mass index tiers.

The $50 copay is a figure for eligible Part D enrollees on covered brand-name products. It is not a price any cash-pay reader is charged.

The two figures, side by side

Two numbers are attached to this program, and they are not the same number. One is what the enrollee pays; the other is what the program records as the net price. Each row below states one figure with no other amount beside it.

Monthly copay paid by an eligible Part D enrollee

$50 per month

Net price under the program

$245

The copay is the reader-facing number: it is what the enrollee is asked to pay each month. The net price is a separate recorded figure. This page does not derive one from the other, and it does not present either as a total, an annual cost or a comparison against a cash price.

A fixed window, not a standing benefit

The bridge is temporary by design. It opens on July 1, 2026 and closes on December 31, 2027. Those are the two dates that bound the program, and they are the only dates this page states about it.

In plain terms: the terms described here belong to a window with an end date written into it. Outside that window there is nothing on this page to rely on, which is why the dates are printed rather than left to context.

Who it is built for

The program is for Medicare Part D enrollees, and eligibility within that group is based on body mass index tiers. Being enrolled in Part D is the first condition; meeting the relevant tier is the second. This page does not reproduce the tiers themselves, because the tier that applies to a given person is a question for their plan.

Because eligibility rests on two conditions rather than one, a reader who has Part D has not thereby established that the bridge applies to them. That is the distinction this section is here to make.

Brand-name products only

The bridge covers brand-name GLP-1 products, and only the products named in the program. Those named products include Foundayo, Wegovy, and the Zepbound KwikPen.

The word “only” is doing real work in that sentence. A product being a GLP-1 medication does not bring it inside the program; being one of the named brand-name products does. This page does not extend the list, and a product not named above should not be read as covered because it appears elsewhere on this site.

What the bridge does not cover

Two exclusions matter more than the rest for readers of this guide.

• It does not cover compounded GLP-1 medications. A compounded preparation is not one of the named brand-name products, so the copay and the net price above do not attach to it.
• It does not apply to people paying cash outside Medicare. The program is built on Part D enrollment, so a reader buying without Medicare is not in it, whatever they are buying.

Read together, those two lines close off the part of the market this guide usually records. Cash prices for compounded medications are a separate subject, and nothing about the bridge changes what those programs charge.

Compounded is not FDA-approved, and not in this program

Compounded semaglutide and compounded tirzepatide are not FDA-approved, and neither is part of this program. Those are two separate statements, and both are needed. The first is about approval; the second is about coverage. A compounded preparation does not become approved by being discussed beside a brand-name product, and it does not enter the bridge because a reader would like it to.

Confirm your own eligibility with your plan

This page is general information. It is not benefits advice, and it is not a determination about any individual. Whether the bridge applies to you depends on your Part D enrollment, your body mass index tier, and the specific product — so the answer belongs to your Part D plan, not to this page.

The practical step is to ask your plan directly, naming the product you were prescribed. If you take one thing from this page, take the two conditions and the window, and let your plan tell you where you stand inside them.

Why this guide tracks cash prices

This guide records what programs charge in cash for compounded medications, and dates every figure it records. A Medicare program is noted here as a Medicare program; its copay and its net price are never used as a cash price, and they are never compared against one. To see the programs themselves, start with the buyer guide; to see how each charge is read, dated and compared, read how we compare.